Art. -Nr.: HY-15767

TAK-632

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF^V600E, BRAF^WT, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.93%
CAS. Nr.: 1228591-30-7
Formel: C₂₇H₁₈F₄N₄O₃S
Molecular Weight:554.52

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

TAK-632 Chemical Structure

CAS. Nr.: 1228591-30-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF^V600E, BRAF^WT, respectively.

IC₅₀ & Target^[1]

C-Raf

1.4 nM (IC₅₀)

Braf

8.3 nM (IC₅₀)

Aurora B

66 nM (IC₅₀)

PDGFRβ

120 nM (IC₅₀)

PDGFRα

610 nM (IC₅₀)

FGFR3

280 nM (IC₅₀)

TIE2

740 nM (IC₅₀)

IKKβ

3700 nM (IC₅₀)

CDK1

790 nM (IC₅₀)

CDK2

580 nM (IC₅₀)

p38α

600 nM (IC₅₀)

GSK3β

500 nM (IC₅₀)

MEK1

3700 nM (IC₅₀)

Alle Raf Isoform-spezifische Produkte anzeigen :

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	GI₅₀	66 nM Compound: 8B, TAK-632	Antiproliferative activity against human A375 cells assessed as growth inhibition after 72 hrs by chemi-luminescence cell viability assay Antiproliferative activity against human A375 cells assessed as growth inhibition after 72 hrs by chemi-luminescence cell viability assay	[PMID: 23906342]
A-375	IC₅₀	12 nM Compound: 8B, TAK-632	Inhibition of BRAF V600E mutant in human A375 cells assessed as phosphorylation of MEK after 2 hrs by Western blotting analysis Inhibition of BRAF V600E mutant in human A375 cells assessed as phosphorylation of MEK after 2 hrs by Western blotting analysis	[PMID: 23906342]
A-375	IC₅₀	16 nM Compound: 8B, TAK-632	Inhibition of BRAF V600E mutant in human A375 cells assessed as phosphorylation of ERK after 2 hrs by Western blotting analysis Inhibition of BRAF V600E mutant in human A375 cells assessed as phosphorylation of ERK after 2 hrs by Western blotting analysis	[PMID: 23906342]
A-375	IC₅₀	160 nM Compound: 127; TAK-632	Antiproliferative activity against human A-375 cells harbouring B-Raf V600E mutant by SRB assay Antiproliferative activity against human A-375 cells harbouring B-Raf V600E mutant by SRB assay	[PMID: 32798788]
A549	IC₅₀	8.5 μM Compound: TAK-632	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26745854]
CHL-1	IC₅₀	2.07 nM Compound: 127; TAK-632	Antiproliferative activity against human CHL-1 cells harbouring wild type B-Raf by SRB assay Antiproliferative activity against human CHL-1 cells harbouring wild type B-Raf by SRB assay	[PMID: 32798788]
COLO 205	IC₅₀	0.025 μM Compound: 3; TAK-632	Cytotoxicity against human COLO205 cells harboring B-Raf V600E mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human COLO205 cells harboring B-Raf V600E mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27155899]
HCT-116	IC₅₀	0.362 μM Compound: 3; TAK-632	Cytotoxicity against human HCT116 cells harboring wild type B-Raf assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells harboring wild type B-Raf assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27155899]
HMCB cell line	IC₅₀	350 nM Compound: 127; TAK-632	Antiproliferative activity against human HMCB cells harbouring wild type B-Raf by SRB assay Antiproliferative activity against human HMCB cells harbouring wild type B-Raf by SRB assay	[PMID: 32798788]
HMV-2 cell line	GI₅₀	200 nM Compound: 8B, TAK-632	Antiproliferative activity against human HMVII cells assessed as growth inhibition after 72 hrs by chemi-luminescence cell viability assay Antiproliferative activity against human HMVII cells assessed as growth inhibition after 72 hrs by chemi-luminescence cell viability assay	[PMID: 23906342]
HMV-2 cell line	IC₅₀	200 nM Compound: 127; TAK-632	Antiproliferative activity against human HMV-2 cells harbouring B-Raf G469V mutant by SRB assay Antiproliferative activity against human HMV-2 cells harbouring B-Raf G469V mutant by SRB assay	[PMID: 32798788]
HT-144	IC₅₀	110 nM Compound: 127; TAK-632	Antiproliferative activity against human HT-144 cells harbouring B-Raf V600E mutant by SRB assay Antiproliferative activity against human HT-144 cells harbouring B-Raf V600E mutant by SRB assay	[PMID: 32798788]
HT-29	CC₅₀	>50 μM Compound: 6; TAK-632	Cytotoxicity against human HT-29 cells measured after 12 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human HT-29 cells measured after 12 hrs by CellTiter-Glo Luminescent assay	[PMID: 31095385]
HT-29	CC₅₀	>50 μM Compound: TAK-632	Cytotoxicity against human HT-29 cells incubated for 16 to 24 hrs measured by cell-titre glo luminescent cell viability assay Cytotoxicity against human HT-29 cells incubated for 16 to 24 hrs measured by cell-titre glo luminescent cell viability assay	[PMID: 36908007]
HT-29	EC₅₀	1.44 μM Compound: 6; TAK-632	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of NFalpha/SM-164/Z-VAD-fmk-induced necroptosis measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of NFalpha/SM-164/Z-VAD-fmk-induced necroptosis measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 31095385]
HT-29	EC₅₀	1.44 μM Compound: TAK-632; 75	Anti-necrotic activity in TSZ induced human HT-29 cells incubated for 16 hrs in presence of TSZ by flow cytometry analysis Anti-necrotic activity in TSZ induced human HT-29 cells incubated for 16 hrs in presence of TSZ by flow cytometry analysis	[PMID: 36346971]
HT-29	EC₅₀	1440 nM Compound: TAK-632	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TCZ)-induced necroptosis pretreated for 8 to 12 hrs Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TCZ)-induced necroptosis pretreated for 8 to 12 hrs	[PMID: 33964444]
HT-29	EC₅₀	1440 nM Compound: TAK-632	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of human TNFalpha/Smac mimetic/Z-VAD-FMK induced necroptosis preincubated with compound for 16 hrs followed by TSZ stimulation for 16 hrs by cell-titre glo luminescent cell viability as Anti-necroptotic activity in human HT-29 cells assessed as inhibition of human TNFalpha/Smac mimetic/Z-VAD-FMK induced necroptosis preincubated with compound for 16 hrs followed by TSZ stimulation for 16 hrs by cell-titre glo luminescent cell viability as	[PMID: 36908007]
HT-29	EC₅₀	1440 nM Compound: TAK-632	Anti-necroptic activity in TSZ (TNFalpha, Smac mimetic and z-VAD-FMK) induced necroptosis in human HT-29 cells assessed as increase in cell viability preincubated for 30 mins pretreated followed by TSZ stimulation and measured after 16 hrs by MTT assay Anti-necroptic activity in TSZ (TNFalpha, Smac mimetic and z-VAD-FMK) induced necroptosis in human HT-29 cells assessed as increase in cell viability preincubated for 30 mins pretreated followed by TSZ stimulation and measured after 16 hrs by MTT assay	[PMID: 37917221]
HT-29	IC₅₀	0.033 μM Compound: 3; TAK-632	Cytotoxicity against human HT-29 cells harboring B-Raf V600E mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells harboring B-Raf V600E mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27155899]
HT-29	IC₅₀	75 nM Compound: 8B, TAK-632	Inhibition of BRAF V600E mutant in human HT-29 cells assessed as phosphorylation of MEK Inhibition of BRAF V600E mutant in human HT-29 cells assessed as phosphorylation of MEK	[PMID: 23906342]
Malme-3M	IC₅₀	50 nM Compound: 127; TAK-632	Antiproliferative activity against human Malme-3M cells harbouring B-Raf V600E mutant by SRB assay Antiproliferative activity against human Malme-3M cells harbouring B-Raf V600E mutant by SRB assay	[PMID: 32798788]
SK-MEL-2	IC₅₀	60 nM Compound: 127; TAK-632	Antiproliferative activity against human SK-MEL-2 cells harbouring wild type B-Raf by SRB assay Antiproliferative activity against human SK-MEL-2 cells harbouring wild type B-Raf by SRB assay	[PMID: 32798788]

In Vitro

TAK-632 inhibits PDGFRβ, FGFR3, GSK3β, CDK2, P38α, PDGFRα, TIE2, and CDK1 with a range of IC₅₀ values from 120-790 nM. CHK1, IKKβ, and MEK1 are inhibited over an IC₅₀ range of 1400-1700 nM. With 1 h of preincubation time, TAK-632 inhibits BRAF and CRAF in an ATP competitive manner (at low ATP concentrations BRAF IC₅₀: 15 nM; CRAF: 8.1 nM). The respective biochemical activity of TAK-632 against BRAF and CRAF reduces to IC₅₀ values of 58 nM and 62 nM at high ATP concentrations.TAK-632 demonstrates strong inhibition of pMEK and pERK in HMVII cells with IC₅₀ values of 49 nM and 50 nM, respectively^[1]. TAK-632 shows strong antiproliferative effects both in A375 and SK-MEL-2 cells (GI₅₀ of 40-190 nM in A375 cells and GI₅₀ of 190-250 nM in SK-MEL-2 cells)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TAK-632 demonstrates dramatically improved solubility (740 μg/mL) in pH 6.8 phosphate buffer and exhibits significant oral absorption (at a dose of 25 mg/kg, AUC, 32.47 μg h/mL; F, 51.7%) in rats. In a dog PK study, 10 mg/kg administration of TAK-632 also shows superior oral bioavailability (F: 108%).Oral single administration of TAK-632 inhibits pERK in tumors at 8 h after its administration over a dose range of 1.9-24.1 mg/kg. In particular, 9.7-24.1 mg/kg dosing with TAK-632 strongly inhibits pERK levels to 11% of the control. TAK-632 exhibits dose-dependent antitumor efficacy without severe body weight reduction over a dose range of 3.9-24.1 mg/kg. Significant tumor regression is observed at 9.7 mg/kg and 24.1 mg/kg (T/C= 2.1% and 12.1%, respectively)^[1]. TAK-632 exhibits potent antitumor efficacy when orally administered at 60 mg/kg once daily (T/C=37%, P<0.001) or at 120 mg/kg once daily (T/C=29%, P<0.001) for 21 days without severe toxicity in NRAS-mutant melanoma using a SK-MEL-2 xenograft model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1228591-30-7
Appearance Solid
Molecular Weight 554.52
Formel C₂₇H₁₈F₄N₄O₃S
Color White to off-white
SMILES

O=C(NC1=CC(OC2=CC=C3N=C(NC(C4CC4)=O)SC3=C2C#N)=CC=C1F)CC5=CC=CC(C(F)(F)F)=C5
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All WB

Sort by:

Journal Impact Factor

Nat Commun

Structure-based design of potent and selective inhibitors targeting RIPK3 for eliminating on-target toxicity in vitro. [Abstract]

2025 May 8;16(1):4288. PMID: 40341069
Br J Pharmacol

Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3. [Abstract]

2019 Jun;176(12):2095-2108. PMID: 30825190

TAK-632 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2019 Jun;176(12):2095-2108. [Abstract]

HT-29 cells are pretreated with TAK-632 (10 μM) followed by stimulation with TSZ at the indicated time points. Cells are lysed and immunoblotted with the indicated antibodies.

TAK-632 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2019 Jun;176(12):2095-2108. [Abstract]

L929 cells are pretreated with TAK-632 (5 μM) followed by stimulated with mTNF-α (20 ng) plus z-VAD-FMK (20 μM) (TZ) at the indicated time points. Cells are lysed and immunoblotted with the indicated antibodies.

TAK-632 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2019 Jun;176(12):2095-2108. [Abstract]

HEK293T cells are transfected with FLAG-RIPK1 or RIPK3-V5. After 12 h, the cells are treated with TAK-632 as the indicated concentrations for 6 h. Cell lysates are then analyzed by SDS-PAGE and immunoblotted with the indicated antibodies. All western data are representative of five independent experiments.
Front Biosci (Landmark Ed)

Hypoxic Regulation of Notch1 Promotes Mitochondrial Fission and Scleral Remodeling in Myopia. [Abstract]

2026 Apr 9;31(4):49381. PMID: 42052847
Cancer Res Commun

A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in Caenorhabditis elegans. [Abstract]

2024 Sep 1;4(9):2454-2462. PMID: 39212544
ACS Comb Sci

Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]

2019 Dec 9;21(12):805-816. PMID: 31689077

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (180.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8034 mL

9.0168 mL

18.0336 mL

5 mM

0.3607 mL

1.8034 mL

3.6067 mL

10 mM

0.1803 mL

0.9017 mL

1.8034 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.51 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[2]

Immunoprecipitated BRAF or CRAF is incubated with recombinant inactive MEK (K97R) at 30°C for 30 minutes in kinase reaction buffer containing ATP/Mg²⁺. RAS/RAF wild-type (A431, CsFb, and HeLa), KRAS-mutant (A549, HCT-116, and MIA PaCa-2), and NRAS-mutant melanoma (GAK, HMV-II, and SK-MEL-2) cells are treated with TAK-632 (0, 0.32, 1.6, 8, 40, 200, 1000 and 5000 nM) at the indicated concentrations for 2 hours. Cell lysates are analyzed by Western blot analysis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Cell viability is assessed (3 replicates) using the Sulforhodamine B assay or by the CellTiter-Glo luminescent cell viability assay. The concentrations of TAK-632 that produced 50% growth inhibition (GI₅₀) are calculated using PCP software. The combination index (CI) is calculated using CalcuSyn software. To investigate the antiproliferative activity of TAK-632, we performed proliferation assays in various cell lines harboring mutated BRAF, NRAS, or KRAS. HMV-II, SK-MEL-2, or A375 cells are cotreated with TAK-632 and TAK-733 at the indicated concentrations for 72 hours. Cell viability is measured. The CI value at EC₅₀ is calculated. A375 cells stably expressing NRAS^Q61K or ΔN-BRAF are cotreated with TAK-632 and TAK-733 at the indicated concentrations for 72 hours. Cell viability is measured. The CI value at EC₅₀ is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
The xenograft-implanted nude mice are used. Mice bearing SK-MEL-2 xenografts are treated once daily for 21 consecutive days with vehicle or TAK-632 at the indicated concentrations (10 mice per each treatment group). Day 0 indicates the beginning of treatment. Tumors are measured twice a week. Mice bearing SK-MEL-2 xenografts are treated once daily (QD) for 3 days with vehicle, TAK-632 at 60 mg/kg (60 mpk), or TAK-632 at 120 mg/kg (120 mpk). Tumor xenografts are obtained at indicated time points after the final treatment and analyzed by Western blot analysis. Individual blots with dividing lines are combined from a single electrophoresis gel. Bars represent densitometric analysis of phospho-ERK, normalized to vehicle-treated control (mean±SD).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Okaniwa M, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. [Content Brief]

[2]. Nakamura A, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Oct 11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8034 mL	9.0168 mL	18.0336 mL	45.0840 mL
	5 mM	0.3607 mL	1.8034 mL	3.6067 mL	9.0168 mL
	10 mM	0.1803 mL	0.9017 mL	1.8034 mL	4.5084 mL
	15 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0056 mL
	20 mM	0.0902 mL	0.4508 mL	0.9017 mL	2.2542 mL
	25 mM	0.0721 mL	0.3607 mL	0.7213 mL	1.8034 mL
	30 mM	0.0601 mL	0.3006 mL	0.6011 mL	1.5028 mL
	40 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1271 mL
	50 mM	0.0361 mL	0.1803 mL	0.3607 mL	0.9017 mL
	60 mM	0.0301 mL	0.1503 mL	0.3006 mL	0.7514 mL
	80 mM	0.0225 mL	0.1127 mL	0.2254 mL	0.5636 mL
	100 mM	0.0180 mL	0.0902 mL	0.1803 mL	0.4508 mL

Keywords

TAK-632

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

TAK-632

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) TAK-632

Alle Raf Isoform-spezifische Produkte anzeigen

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

TAK-632 Related Classifications

HY-15767 Related Classifications